Aberdeen Group
CRL icon

Aberdeen Group’s Charles River Laboratories CRL Stock Holding History

Aberdeen Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Buy
135,799
+21,972
+19% +$3.91M 0.04% 330
2026
Q1 		$19.6M Buy
113,827
+16,826
+17% +$3.12M 0.03% 435
2025
Q4 		$19.3M Buy
97,001
+88,853
+1,090% +$16.1M 0.03% 442
2025
Q3 		$1.2M Buy
8,148
+3,021
+59% +$480K ﹤0.01% 824
2025
Q2 		$778K Buy
5,127
+1,586
+45% +$211K ﹤0.01% 845
2025
Q1 		$528K Sell
3,541
-14,276
-80% -$2.39M ﹤0.01% 870
2024
Q4 		$3.29M Sell
17,817
-1,027
-5% -$198K 0.01% 708
2024
Q3 		$3.71M Sell
18,844
-106,170
-85% -$22.1M 0.01% 695
2024
Q2 		$25.8M Buy
125,014
+13,011
+12% +$2.95M 0.05% 322
2024
Q1 		$30.3M Sell
112,003
-9,804
-8% -$2.34M 0.06% 306
2023
Q4 		$28.8M Buy
121,807
+109,275
+872% +$21.5M 0.06% 299
2023
Q3 		$2.46M Sell
12,532
-404
-3% -$82.9K 0.01% 663
2023
Q2 		$2.72M Sell
12,936
-150
-1% -$29.8K 0.01% 680
2023
Q1 		$2.64M Sell
13,086
-10
-0.1% -$2.27K 0.01% 691
2022
Q4 		$2.85M Buy
13,096
+978
+8% +$214K 0.01% 654
2022
Q3 		$2.38M Buy
12,118
+102
+0.8% +$22K 0.01% 678
2022
Q2 		$2.6M Sell
12,016
-425
-3% -$104K 0.01% 675
2022
Q1 		$3.59M Sell
12,441
-2,348
-16% -$724K 0.01% 655
2021
Q4 		$5.57M Sell
14,789
-880
-6% -$342K 0.01% 618
2021
Q3 		$6.59M Buy
15,669
+2,544
+19% +$1.06M 0.01% 598
2021
Q2 		$4.86M Buy
+13,125
New +$4.38M 0.01% 652

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Aberdeen Group's CRL Position: Q2 2026 in Review

Aberdeen Group increased its Charles River Laboratories (CRL) stake by 19% in Q2 2026, buying an estimated $3.91M and bringing the position to 135,799 shares worth $30.8M. The position accounts for 0.04% of the portfolio, ranked #330.

Aberdeen Group first reported a position in CRL in Q2 2021 and has held it in 21 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Aberdeen Group held 135,799 shares of Charles River Laboratories worth $30.8M as of Q2 2026.
  • Aberdeen Group bought 21,972 Charles River Laboratories shares in Q2 2026, an estimated $3.91M.
  • Charles River Laboratories made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #330 holding.
  • Aberdeen Group first reported a position in Charles River Laboratories in Q2 2021 and has held it in 21 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.